First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon

IF 122.7 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nature Reviews. Drug Discovery Pub Date : 2025-02-17 DOI:10.1038/d41573-025-00029-7

Ken Garber

引用次数: 0

Abstract

Scholar Rock’s myostatin blocker has shown its efficacy in spinal muscular atrophy, and the 28-year-old myostatin field is now looking to muscle in on obesity. Scholar Rock’s myostatin blocker has shown its efficacy in spinal muscular atrophy, and the 28-year-old myostatin field is now looking to muscle in on obesity.

Abstract Image

查看原文本刊更多论文

首款肌肉生长抗体即将提交美国食品药品管理局，肥胖症治疗机会近在眼前

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.